| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals, Inc. (MDGL) has 13 insiders with recent SEC Form 4 filings, including 54 buys and 70 sells. MDGL is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 452.2K | $241.87M | - | |
| Dir | 205.0K | $109.65M | - | |
| Dir | 200.0K | $106.99M | - | |
| CEO | 150.1K | $80.27M | - | |
| Dir | 29.7K | $15.88M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 1,958 | $553.11 | $1,082,986.25 | -1.7% | -20.3% | - | |
| Nov 13, 2025 | Levy Richard S | Director | Sale+OE | 8,500 | $520.96 | $4,428,197.57 | -2.4% | -6.6% | - | |
| Nov 5, 2025 | Bate Kenneth | Director | Sale+OE | 16,575 | $484.30 | $8,027,354.15 | -15.2% | +1.4% | - | |
| Sep 9, 2025 | Sibold William John | President And CEO | Sell | 7,279 | $445.63 | $3,243,740.77 | -6.6% | +26.7% | - | |
| Aug 21, 2025 | Sibold William John | President And CEO | Sell | 7,616 | $400.18 | $3,047,756.37 | -3.3% | +36.5% | - | |
| Aug 20, 2025 | Baker Bros. Advisors LP59 | Director | Buy | 97,065 | $380.58 | $36,941,197.13 | +0.4% | +42.7% | - | |
| Aug 18, 2025 | Kelley Shannon T | General Counsel | Sell | 1,304 | $367.81 | $479,626.86 | -1.7% | +41.4% | - | |
| Aug 18, 2025 | Baker Bros. Advisors LP59 | Director | Buy | 68,618 | $364.04 | $24,979,827.15 | +0.2% | +41.4% | - | |
| Aug 15, 2025 | Bate Kenneth | Director | Sale+OE | 10,000 | $365.20 | $3,652,008.56 | -22.7% | +39.2% | - | |
| Aug 13, 2025 | Friedman Paul A | Director | Sale+OE | 129,172 | $370.24 | $47,825,149.36 | -2.7% | +45.0% | - |